Artificial Intelligence (AI) In Biopharmaceuticals Market Trends and Opportunities Across 2026–2030
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Much Is The Artificial Intelligence (AI) In Biopharmaceuticals Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?
The market size for artificial intelligence (AI) in biopharmaceuticals has seen substantial expansion in recent years. This market is anticipated to expand from $2.1 billion in 2025 to $2.79 billion in 2026, achieving a compound annual growth rate (CAGR) of 33.0%. The growth observed in previous periods is a result of the early embrace of AI in pharmaceutical research, enhanced computational power, increased investment in biopharmaceutical research and development (R&D), the integration of omics data, and the proliferation of cloud-based data storage.
The artificial intelligence (AI) in biopharmaceuticals market is set for significant expansion in the coming years. It is projected to reach $8.77 billion by 2030, growing at a compound annual growth rate (CAGR) of 33.1%. This anticipated growth throughout the forecast period stems from advancements in machine learning algorithms, the increasing availability of AI-enabled laboratory equipment, a greater embrace of predictive analytics, the emergence of collaborative AI-biopharma platforms, and government incentives supporting AI in healthcare. Prominent trends for the forecast period involve AI-driven drug discovery, the application of predictive analytics in clinical trials, the automation of laboratory processes, the integration of real-world data, and the optimization of personalized treatments.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14251&type=smp
What Major Drivers Are Influencing Demand In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
The increasing occurrence of chronic diseases is projected to drive the expansion of the artificial intelligence (AI) in biopharmaceuticals market moving ahead. These are enduring conditions that typically advance gradually, potentially lasting for years or a lifetime, often stemming from lifestyle choices, an aging populace, genetic susceptibilities, and environmental influences. AI within biopharmaceuticals is increasingly employed for managing chronic diseases by analyzing vast amounts of varied data, pinpointing patterns, and customizing treatment strategies. For instance, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, approximately 194 million U.S. adults, constituting 76.4%, had at least one chronic condition. The prevalence stood at 59.5% for young adults, 78.4% for midlife adults, and 93.0% for older adults. Consequently, the rising prevalence of chronic diseases stands as a significant driver for the growth of the artificial intelligence (AI) in the biopharmaceuticals market.
What Major Segment Divisions Exist Within The Artificial Intelligence (AI) In Biopharmaceuticals Market?
The artificial intelligence (ai) in biopharmaceuticals market covered in this report is segmented –
1) By Offering: Hardware, Software, Services
2) By Deployment: Cloud, On-Premises
3) By Technology: Machine Learning, Natural Language Processing, Deep Learning, Other Technologies
4) By Application: Drug Discovery, Precision Medicine
5) By End-Users: Manufacturers, Contract Research Organizations, Academic And Government Research Institutes
Subsegments:
1) By Hardware: High-Performance Computing Systems, AI-Enabled Laboratory Equipment, Data Storage Solutions
2) By Software: Drug Discovery Platforms, Predictive Analytics Tools, Natural Language Processing Solutions
3) By Services: Consulting Services, Implementation And Integration Services, Data Management And Analytics Services, Training And Support Services
How Are Trends Shaping The Direction Of The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Leading companies in artificial intelligence (AI) within biopharmaceuticals are focused on developing cutting-edge advancements, such as AI-powered solutions for target and lead identification, to accelerate drug discovery and precision medicine, ultimately transforming life sciences organizations. These solutions for drug discovery and precision medicine encompass a range of innovative methods for developing new medications and tailoring treatments to individual patients. For instance, in May 2023, Google LLC, a US-based provider of cloud computing services, launched two new AI tools called target and lead identification suites. These tools are designed to assist researchers in predicting and understanding protein structures, a fundamental aspect of drug development. Additionally, this suite will enable researchers to ingest, store, analyze, and share vast amounts of genomic data, which is crucial for precision medicine. These tools also aim to streamline the drug discovery process, reduce expenses, and bring new treatments to market more quickly. By providing efficient data management, precise predictions of protein structures, and advanced genomic analysis capabilities, these tools intend to revolutionize drug development processes and enhance patient outcomes.
Which Companies Are Leading Innovation In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
Major companies operating in the artificial intelligence (ai) in biopharmaceuticals market are Exscientia Limited, DeepMind Technologies Limited, Schrödinger Inc., XtalPi Inc., ConcertAI Inc., Insilico Medicine Inc., Recursion Pharmaceuticals, BenevolentAI, BioXcel Therapeutics, Atomwise Inc., BioAge Labs Inc., GNS Healthcare, Berg Health, Deep 6 AI Inc., Cloud Pharmaceuticals Inc., Numerate Inc., AI Therapeutics, Envisagenics, twoXAR Inc., Cyclica Inc.
Read the full artificial intelligence (ai) in biopharmaceuticals market report here:
Which Region Shows The Strongest Potential For Future Growth In The Artificial Intelligence (AI) In Biopharmaceuticals Market?
North America was the largest region in the artificial intelligence (AI) in biopharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence (ai) in biopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Artificial Intelligence (AI) In Biopharmaceuticals Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=14251&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Biopharmaceuticals Market 2026, By The Business Research Company
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Artificial Intelligence In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Precision Medicine Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
